According to filings with the U.S. Securities and Exchange Commission, XDemics is raising up to $7,399,999.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About XDemics
XDemics, a Caltech spinout, is fundamentally improving the way cells are grown. Weve addressed a primary bottleneckthe basic inability to efficiently transfer oxygen in media during cell growth. Our high-density cell respiration (HDCR) technology enables mammalian cells to grow at 20- to 100-fold higher densitieswhether in a Petri dish or a large-scale bioreactor. As a result, scientists and manufacturers can produce more high-quality, viable cells in far less space and time, dramatically slashing R&D and manufacturing costs. From the lab bench to industrial-scale production, HDCR is transformative. One Expansify Petri dish replaces 25 traditional polystyrene dishes, vastly accelerating biomedical innovation while cutting costs. With predictable process scale-up, our Profusion-Midi 5L and Profusion-Max 50L bioreactors can respectively generate up to 110 trillion cells, eliminating the need for massive, complicated 2002000L stirred-tank vessels. HDCR systems deliver high-quality cell and gene therapies more efficiently, reducing the overall cost of these advanced medicines by up to 80%, achieving cost parity with biologics and making these life-changing treatments more accessible worldwide. Our laboratory facilities are located on the beautiful campus of the world-famous Buck Institute in Marin County, California.

To learn more about XDemics, visit https://www.xdemics.com/
XDemics Linkedin Page: https://www.linkedin.com/company/xdemics-corporation/

Contact:
Christopher Thanos, Chief Executive Officer
415-637-6691
https://www.linkedin.com/in/christopher-thanos-35972a37/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.